AbbVie Inc. ABBV

ABBV Company Overview

AbbVie Inc. is a global, research-driven biopharmaceutical company focused on the discovery, development, and commercialization of advanced therapies for serious and chronic diseases. The company operates primarily within the biopharmaceuticals industry, with core therapeutic areas spanning immunology, oncology, neuroscience, eye care, and virology. AbbVie’s revenues are largely driven by branded prescription medicines, with flagship products including Humira, Skyrizi, Rinvoq, Botox, and Venclexta, which serve large patient populations across autoimmune, cancer, and neurological conditions.

AbbVie was established in 2013 as a spin-off from Abbott Laboratories, becoming an independent publicly traded company following the separation of Abbott’s proprietary pharmaceutical business. Since its formation, AbbVie has pursued a strategy of combining internally developed medicines with targeted acquisitions to diversify beyond Humira and strengthen long-term growth. The company is widely recognized for its scale in immunology and for leveraging lifecycle management, global commercial infrastructure, and sustained R&D investment as strategic advantages.